Global Drug Eluting Stent Market Set to Grow at 5.2% CAGR Through 2036

 

Rising PCI procedures, wider adoption of newer-generation stents, and growing demand for complex coronary interventions are supporting market expansion.

November 3, 2026 — The global drug eluting stent market is projected to increase from USD 9.5 billion in 2026 to USD 15.8 billion by 2036, expanding at a compound annual growth rate (CAGR) of 5.2%, according to Fact.MR. The market was valued at USD 8.9 billion in 2025. Continued demand for coronary revascularization procedures and the adoption of newer-generation drug-eluting stent technologies are expected to create an absolute dollar opportunity of USD 6.3 billion over the forecast period.

The expansion reflects the continued importance of drug-eluting stents in treating coronary artery disease (CAD). Hospitals and interventional cardiology centers remain the primary demand centers, particularly as physicians address complex coronary lesions and manage patients requiring different antiplatelet therapy strategies.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15040

Drug Eluting Stent Market Growth Driven by Newer-Generation Technologies

Drug-eluting stents (DES) are specially coated coronary devices that release medication gradually after implantation. The medication helps prevent restenosis, a condition in which an artery narrows again following angioplasty. Their role in contemporary percutaneous coronary intervention (PCI) continues to support demand across established and emerging healthcare markets.

According to Fact.MR, newer-generation DES platforms remain central to contemporary coronary revascularization practice. Manufacturers are refining drug formulations, polymer technologies, and delivery systems to address changing procedural requirements.

The European Society of Cardiology's 2024 clinical communication identifies contemporary DES as benchmark comparators in coronary revascularization research. This reinforces their established position in treatment pathways and clinical evaluations.

Another important consideration is the growing complexity of PCI procedures. Interventional cardiologists increasingly require devices that can navigate challenging anatomy while maintaining effective lesion coverage. Product performance therefore depends on more than the metallic scaffold itself.

Durable Polymer Drug Eluting Stents Hold Leading Product Share

Durable polymer drug-eluting stents are expected to account for approximately 41% of the market in 2026. Their established clinical use and integration into standard coronary intervention workflows support this position.

Bioabsorbable polymer DES also present opportunities for manufacturers. These platforms attract attention where polymer resorption and healing characteristics influence product selection. Specialty stents address more demanding anatomical requirements, including bifurcations and large proximal vessels.

By drug type, everolimus-eluting stents are projected to capture approximately 29% share in 2026. Their continued representation in contemporary coronary stent portfolios supports demand. Boston Scientific's SYNERGY XD is one example of an everolimus-eluting platform featuring a bioabsorbable polymer design.

Coronary Artery Disease Remains the Primary Application

Coronary artery disease is projected to represent approximately 52% of the drug eluting stent market in 2026. DES remain closely associated with routine PCI procedures for treating coronary lesions.

Acute coronary syndromes and complex PCI also contribute to market demand. Procedures involving chronic total occlusions, bifurcations, and large proximal vessels require devices suited to specific anatomical challenges.

Hospitals are expected to account for approximately 47% of total market demand in 2026. This position reflects the concentration of scheduled and acute PCI procedures in hospital-based catheterization laboratories and specialist cardiac facilities.

India Leads Regional Drug Eluting Stent Market Expansion

Asia Pacific is expected to offer strong long-term opportunities as interventional cardiology capacity expands and access to coronary procedures improves.

India is projected to record the fastest growth among the countries assessed, with a CAGR of 6.1% through 2036. Increasing PCI adoption and expanding cardiac care infrastructure are supporting this outlook.

China follows at 5.8%, reflecting substantial coronary intervention volumes and growing catheterization laboratory capacity. The United States is expected to expand at 5.1%, supported by established PCI infrastructure and replacement demand for newer-generation devices.

Germany is projected to register a CAGR of 4.7%, while Brazil is expected to grow at 4.5% through 2036. Both markets reflect continued demand for contemporary coronary intervention technologies.

Complex PCI Creates New Opportunities for Manufacturers

The market is evolving beyond conventional stent specifications. Deliverability, restenosis control, polymer strategy, and flexibility are increasingly relevant considerations when evaluating coronary stent platforms.

One notable industry example is Medtronic's Resolute Onyx platform. Medtronic positions the device for complex PCI and selected high-bleeding-risk patients, supported by evidence involving shorter dual antiplatelet therapy (DAPT) durations.

This positioning highlights an important commercial consideration. Stent manufacturers must demonstrate how product characteristics address specific procedural and patient requirements rather than relying solely on conventional device specifications.

However, established clinical practices and reimbursement considerations remain important restraints. DAPT management following PCI also influences treatment decisions, requiring physicians to balance stent selection with post-procedure therapy.

Fact.MR identifies complex PCI as a key opportunity area, particularly for platforms offering improved deliverability and coverage across challenging coronary anatomy.

Competitive Landscape and Industry Outlook

The competitive environment includes established medical device manufacturers with broad interventional cardiology portfolios. Key companies operating in the drug-eluting stent market include Medtronic, Boston Scientific, Abbott, Biotronik, MicroPort, and Cardinal Health.

Competition increasingly centers on drug-elution performance, polymer design, flexibility, and suitability for complex coronary procedures. Manufacturers with established hospital relationships and technically differentiated platforms are positioned to address evolving clinical requirements.

Shambhu Nath Jha of Fact.MR states, "This market should be viewed as a coronary revascularization performance category rather than a mature metal-device segment. Buyers are not only paying for scaffolding. They are paying for deliverability, restenosis control, and procedural confidence across complex lesion sets."

The outlook remains tied to sustained PCI demand and continued adoption of newer-generation DES. With the market expected to reach USD 15.8 billion by 2036, product differentiation and regional expansion will remain important considerations for industry participants.

Market intelligence: Fact.MR's analysis covers product type, drug type, application, end use, and regional demand across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The forecast uses a hybrid top-down and bottom-up approach, incorporating PCI procedure intensity, product adoption, lesion-complexity trends, and primary interviews with cardiology and catheterization laboratory stakeholders.

View Related Reports :

https://social.mytamam.com/blogs/1073/Capillary-Blood-Collection-Devices-Market-to-Reach-USD-4-18

https://ayushjadhavblogs.blogspot.com/2026/11/global-lecithin-market-set-for-strong.html

https://www.panchit.com/blogs/132828/China-and-USA-Emerge-as-Key-Growth-Markets-for-Rheumatoid

https://sohomoy.com/blogs/75874/Demand-for-Viral-Vector-Manufacturing-Solutions-Rises-Across-Research-Facilities

About Fact.MR

Fact.MR is a market research and consulting firm providing industry intelligence, market forecasts, and strategic analysis across multiple sectors. Its research combines quantitative modelling with industry insights to help businesses understand market developments, assess growth opportunities, and make informed decisions.